Bio-Path Holdings, Inc. (BPTH)
| Market Cap | 35.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.77M |
| Shares Out | 6.96M |
| EPS (ttm) | -1.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,231 |
| Open | 5.19 |
| Previous Close | 5.24 |
| Day's Range | 4.99 - 5.19 |
| 52-Week Range | 3.12 - 24.34 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 12.50 (+148.0%) |
| Est. Earnings Date | Nov 11, 2021 |
About BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also d...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BPTH stock is "Buy" and the 12-month stock price forecast is 12.50.
News
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients.
BPTH Stock: The Good News That Has BioPath Investors Smiling Today
BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today ap...
BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%
BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Tha...
Why Bio-Path Holdings Shares Are Surging Higher Today
Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 i...
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b trial, si...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute...
Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Pro...
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021
HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf...
Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna...
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003
Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat Cancers Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expressi...
Bio-Path Holdings Reports First Quarter 2021 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021
HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfo...
Bio-Path Announces Publication in Biomedicines
Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug D...
Why Acadia Pharma, Bio-path And Cidara Are Moving Today
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejec...
Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leuke...
Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapie...
Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine...
HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...
Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade
Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting
HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop ...
Bio-Path Holdings Reports Full Year 2020 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...
Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock
HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a ...
Why Bio-Path's Stock Is Surging Higher Today
Bio-Path (NASDAQ: BPTH) shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Bio-Path Holdings Inc...
BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today
Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform. The post BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today appeared...